Efficacy

Xeloda (Capecitabine) in Breast Cancer Treatment

Xeloda (capecitabine) is an oral chemotherapy drug that is used in the treatment of breast cancer. It is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, where it inhibits DNA synthesis and slows the growth of cancer cells. Xeloda is specifically indicated for the treatment of patients with metastatic breast cancer when standard anthracycline-containing therapy has failed, or for patients who are not candidates for such therapies. Clinical trials have demonstrated the efficacy of Xeloda in improving survival rates and reducing tumor size in patients with advanced breast cancer, especially when used in combination with other chemotherapeutic agents.

Trodelvy (Sacituzumab Govitecan-hziy) in Breast Cancer Treatment

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class antibody-drug conjugate (ADC) specifically designed for the treatment of metastatic triple-negative breast cancer (TNBC), a type of cancer that lacks the three most common types of receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2 gene. Trodelvy works by targeting the Trop-2 receptor, which is expressed in the majority of breast cancers, and delivering the anti-cancer drug govitecan directly to the cancer cells. This targeted approach helps to minimize the impact on healthy cells and allows for the delivery of a potent chemotherapy agent directly to the tumor.

The efficacy of Trodelvy was demonstrated in a pivotal Phase III clinical trial, which showed a significant improvement in overall survival and progression-free survival in patients with metastatic TNBC who had received at least two prior therapies for metastatic disease. The results indicated a meaningful clinical benefit, with a substantial increase in median overall survival compared to standard single-agent chemotherapy. Trodelvy has been granted accelerated approval by the FDA based on these results, with continued approval contingent upon verification and description of clinical benefit in confirmatory trials.

Both Xeloda and Trodelvy represent important advancements in the treatment of breast cancer, offering hope to patients with advanced disease. Xeloda provides an oral chemotherapy option for those who have previously been treated with anthracycline-based therapies, while Trodelvy offers a new targeted treatment for patients with the particularly aggressive and difficult-to-treat triple-negative form of breast cancer. Ongoing research continues to evaluate the full potential of these drugs in various combinations and settings within breast cancer therapy.